NEW YORK, Nov. 17, 2016 /PRNewswire/ -- Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has secured up to $11 million in new financing from a single family office that is an existing investor. The financing includes the sale of a $1 million convertible note and up to $10 million in future equity sales at prevailing market prices in increments of at least $1 million per month.
Dr. Daniel Teper, Immune’s CEO commented: “We appreciate the continuous commitment of our investors to support this financing of Immune, which will be dedicated to the advancement of bertilimumab clinical development. We are also implementing a strategy to unlock the value of other assets through the establishment of new, privately-funded companies which will be partially owned by Immune.”
Immune continues to accrue patients in two phase 2 clinical trials for bertilimumab, a first-in-class monoclonal antibody targeting eotaxin-1: an open label 10 patient trial in the treatment of bullous pemphigoid, an orphan auto-immune dermatological condition, and a double-blind, placebo-controlled, 42 patient trial in moderate-to-severe ulcerative colitis, a gastrointestinal inflammatory condition. In both conditions, a significant number of patients have elevated levels of eotaxin-1, which is also considered a biomarker of disease severity. Targeting patients with elevated eotaxin-1 offers the potential to select patients who may be more likely to respond to treatment. Additionally in 2017, Immune plans to initiate a phase 2 trial in severe atopic dermatitis, a condition where eotaxin1 plays an important role, and to explore the role of eotaxin-1 in patients with nonalcoholic steatohepatitis (NASH).
Immune is also moving forward with forming three private companies separate from the development of bertilimumab, focusing on Immuno-Oncology, Dermatology, and Pain & Neurology respectively. The Immuno-Oncology subsidiary will focus on Ceplene, which recently received guidance from the FDA for a pivotal phase 3 Overall Survival study in remission maintenance for Acute Myeloid Leukemia, and novel bispecific antibodies targeting immune check points and other novel targets. The Dermatology subsidiary will focus on the application of nanotechnology to dermatology. The lead program is a topical cyclosporine for the treatment of psoriasis and atopic dermatitis. The Pain and Neurology subsidiary will focus on AmiKet® for the treatment of peripheral neuropathic pain with the subsidiary’s new management looking at complementary assets.
About Immune Pharmaceuticals Inc.:
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune’s lead product candidate, bertilimumab, is in Phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn’s disease, severe asthma and Non-Alcoholic Steato-Hepatitis (NASH), an inflammatory liver disease. Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune’s oncology pipeline includes Ceplene® which is in late stage clinical development for maintenance remission in Acute Myeloid Leukemia (AML) in combination with IL-2. Additional oncology pipeline includes Azixa® and crolibulin, Phase II clinical stage vascular disrupting agents, and novel technology platforms; bispecific antibodies and NanomAbs. Maxim Pharmaceuticals Inc., Immune’s pain and neurology subsidiary is developing AmiKet and AmiKet Nano for the treatment of neuropathic pain. For more information, visit Immune’s website at www.immunepharma.com, the content of which is not a part of this press release.
Forward-Looking Statement
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal” or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab, Ceplene, Azixa, AmiKet, AmiKet Nano, LidoPain or NanoCyclo will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property; risks associated with the contemplated transaction with NPT. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharma.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immune-pharmaceuticals-secures-up-to-11-million-in-new-financing-to-be-deployed-with-a-focus-on-bertilimumab-clinical-development-300364954.html
SOURCE Immune Pharmaceuticals Inc.
